Prototropic tautomerism and microsolvation in antitumor drug imexon: a DFT study

被引:5
作者
Kheffache, Djaffar [1 ,2 ]
Guemmour, Hind [2 ]
Ouamerali, Ourida [1 ]
机构
[1] USTHB Univ, Fac Chim, Lab Physicochim Theor & Chim Informat, Algiers 16111, Algeria
[2] UMBB Univ, Dept Chem, Boumerdes 35000, Algeria
关键词
Imexon; Rare tautomers; Hydration; Proton transfer; DFT; MYELOMA CELLS; INDUCTION; APOPTOSIS; MOLECULES;
D O I
10.1007/s11224-012-9968-3
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Density functional theory method, at the B3LYP/6-311+G(d, p) level has been used to explore the geometries, relative energies, and electronic properties of all hypothetically possible prototropic tautomers of imexon. The specific interactions of the tautomeric forms of imexon with one and two solvating water molecules have been investigated. The relative stability order of the complexes remains unchanged upon interaction with one water molecule. The addition of a second water molecule, however, stabilizes the oxo-amino form more than the oxo-imino structure. The bulk water environment has been simulated by a combination of microhydration and the conductor-like polarizable continuum model. The energy profile corresponding to the prototopic tautomerisms connecting oxo-imino form with oxo-amino, hydroxyl-amino, and one rare tautomer has been studied. We found that the tautomerism activation barriers are high enough as to conclude that only the oxo-imino tautomer should be found in the gas phase. Our results present clear evidence that microhydration with one and two solvating water molecules considerably lower these barriers by a concerted multiple proton transfer mechanism.
引用
收藏
页码:1547 / 1557
页数:11
相关论文
共 23 条
[1]   DENSITY-FUNCTIONAL THERMOCHEMISTRY .3. THE ROLE OF EXACT EXCHANGE [J].
BECKE, AD .
JOURNAL OF CHEMICAL PHYSICS, 1993, 98 (07) :5648-5652
[2]  
BHASHYAM SI, 2004, J MED CHEM, V47, P218
[3]   Energies, structures, and electronic properties of molecules in solution with the C-PCM solvation model [J].
Cossi, M ;
Rega, N ;
Scalmani, G ;
Barone, V .
JOURNAL OF COMPUTATIONAL CHEMISTRY, 2003, 24 (06) :669-681
[4]   LC-UV method development and validation for the investigational anticancer agent imexon and identification of its degradation products [J].
den Brok, MWJ ;
Nuijen, B ;
Hillebrand, MJX ;
Lutz, C ;
Opitz, HG ;
Beijnen, JH .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2005, 38 (04) :686-694
[5]  
Dorr RT, 2005, J GASTROINTEST CANC, V36, P15, DOI 10.1385/IJGC:36:1:015
[6]   PRECLINICAL PHARMACOKINETICS AND ANTITUMOR-ACTIVITY OF IMEXON [J].
DORR, RT ;
LIDDIL, JD ;
KLEIN, MK ;
HERSH, EM .
INVESTIGATIONAL NEW DRUGS, 1995, 13 (02) :113-116
[7]   Phase I trial of imexon in patients with advanced malignancy [J].
Dragovich, Tomislav ;
Gordon, Michael ;
Mendelson, David ;
Wong, Lucas ;
Modiano, Manuel ;
Chow, H. H. Sherry ;
Samulitis, Betty ;
O'Day, Steven ;
Grenier, Kathryn ;
Hersh, Evan ;
Dorr, Robert .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) :1779-1784
[8]   Induction of mitochondrial changes in myeloma cells by imexon [J].
Dvorakova, K ;
Waltmire, CN ;
Payne, CM ;
Tome, ME ;
Briehl, MM ;
Dorr, RT .
BLOOD, 2001, 97 (11) :3544-3551
[9]   Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent imexon [J].
Dvorakova, K ;
Payne, CM ;
Tome, ME ;
Briehl, MM ;
McClure, T ;
Dorr, RT .
BIOCHEMICAL PHARMACOLOGY, 2000, 60 (06) :749-758
[10]  
Frisch MJ, 2003, GAUSSIAN 03 REVISION